94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Metabolomics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1544774
Early potential metabolic biomarkers of T1 stage lung adenocarcinoma based on serum metabolomics
Provisionally accepted- Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
AbstractBackground: This study aims to investigate serum metabolite changes in patients with early-stage (T1) lung adenocarcinoma, identify potential diagnostic biomarkers, and establish an early warning mechanism for T1 stage lung adenocarcinoma.Methods: The study included two groups: a lung adenocarcinoma group and a healthy control group. Serum samples underwent non-targeted metabolomics analysis. Total ion chromatograms (TIC) were generated to assess system stability. Chromatographic data were analyzed using multivariate statistical methods, including principal component analysis (PCA) for dimensionality reduction. Partial least squares discriminant analysis (PLS-DA) further validated PCA findings. Variables with VIP scores >1.0 in the PLS-DA model were selected, combined with ANOVA and T-tests (P < 0.05), to identify differentially expressed metabolites. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic performance of selected metabolites.Results: Serum metabolites significantly differed between the lung adenocarcinoma group and the healthy control group. Multivariate statistical analysis and ROC curve evaluation identified four potential diagnostic biomarkers: Cortisol, 3-Oxo-OPC4-CoA, PE-NMe(14:1(9Z)/14:1(9Z)), and Ceramide (d18:1/9Z-18:1), with AUC values of 0.930, 0.895, 0.890, and 0.795, respectively.Conclusion:Cortisol,3-Oxo-OPC4-CoA,PE-NMe(14:1(9Z)/14:1(9Z)), and Ceramide (d18:1/9Z-18:1) exhibit significantly altered metabolic levels in T1 stage lung adenocarcinoma patients and can serve as metabolic biomarkers. These markers may enhance the sensitivity and specificity of early diagnosis, facilitating improved detection of T1 stage lung adenocarcinoma.
Keywords: ：lung adenocarcinoma, biomarker, Metabolomics, Lipid Metabolism, LC-MS
Received: 17 Dec 2024; Accepted: 09 Apr 2025.
Copyright: © 2025 Wu, Zheng, Guo, Wang, Zhu, Zhao and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bin Wu, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Ye Xu, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.